NCT07264010 2025-12-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
Clinical Trials
9 trialsNCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT02794337 2022-04-27
TACE-SBRT
Tata Memorial Hospital
Phase 2/3 Unknown
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown
NCT02474290 2019-08-26
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT02220088 2019-01-11
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Sun Yat-sen University
Phase 2/3 Terminated
NCT01932385 2018-02-14
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Qingdao Central Hospital
Phase 2/3 Completed
NCT01901692 2017-09-18
START
Asan Medical Center
Phase 2/3 Completed